ONO PHARMACEUTICAL CO., LTD.
609Patents
250Active
609Granted
52Portfolio score
Filing activity: Dec 19, 1964 → Sep 22, 2023 · 82 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8008449B2 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics | Emerging Cross-Sectional Technologies | 812 | Active |
| US7595048B2 | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 | Emerging Cross-Sectional Technologies | 298 | Expired |
| US8728474B2 | Immunopotentiative composition | Emerging Cross-Sectional Technologies | 213 | Active |
| US8168179B2 | Treatment method using anti-PD-L1 antibody | Emerging Cross-Sectional Technologies | 184 | Active |
| US7563869B2 | Substance specific to human PD-1 | Chemistry; Metallurgy | 161 | Expired |
| US9073994B2 | Immunopotentiative composition | Emerging Cross-Sectional Technologies | 139 | Active |
| US9067999B1 | Immunopotentiative composition | Emerging Cross-Sectional Technologies | 136 | Active |
| US9084776B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 134 | Active |
| US5698520A | Peptide related to human programmed cell death and DNA encoding the same | Chemistry; Metallurgy | 117 | Expired |
| US9492540B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 116 | Active |
| US9358289B2 | Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies | Emerging Cross-Sectional Technologies | 112 | Active |
| US5629204A | Peptide related to human programmed cell death and DNA encoding it | Chemistry; Metallurgy | 110 | Expired |
| US9387247B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 98 | Active |
| US9492539B2 | Monoclonal antibodies to Programmed Death 1 (PD-1) | Emerging Cross-Sectional Technologies | 96 | Active |
| US5439895A | 4-aminoquinazoline derivatives | Chemistry; Metallurgy | 77 | Expired |
| US4483846A | Long-lasting three-layered pharmaceutical film preparations | Human Necessities | 74 | Expired |
| US8557803B2 | Purinone derivative | Human Necessities | 65 | Active |
| US4552751A | Long-lasting multi-layered film preparation | Human Necessities | 63 | Expired |
| US9402899B2 | Immunopotentiative composition | Emerging Cross-Sectional Technologies | 62 | Active |
| US9242977B2 | Trk-inhibiting compound | Emerging Cross-Sectional Technologies | 61 | Active |
| US9393301B2 | Immunopotentiative composition | Emerging Cross-Sectional Technologies | 57 | Active |
| US5723145A | Transdermal absorption preparation | Human Necessities | 54 | Expired |
| US6448290B1 | Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient | Chemistry; Metallurgy | 54 | Expired |
| US6677333B1 | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient | Chemistry; Metallurgy | 52 | Expired |
| US9439962B2 | Immunopotentiative composition | Emerging Cross-Sectional Technologies | 52 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.